Dianthus director sells 599 shares after option exercise
Dianthus Therapeutics director Paula Soteropoulos reported an exercise-and-sale of 599 shares of common stock.
Rhea-AI Filing Summary
Dianthus Therapeutics director Paula Soteropoulos reported an exercise-and-sale of 599 shares of common stock. She exercised stock options to acquire 599 shares at $8.44 per share, then sold 599 shares in the open market at $85.47 per share on May 8, 2026.
The stock option related to 599 underlying shares and had an expiration date of June 6, 2032. A footnote states the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 599 shares ($46K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Soteropoulos Paula
Role
Director
Sold
599 shs ($51K)
Approx. gross sale proceeds
$51K
Approx. exercise cost
$5K
Approx. pre-tax spread
$46K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 599 | $0.00 | $0.00 |
| Exercise | Common Stock | 599 | $8.44 | $5K |
| Sale | Common Stock | 599 | $85.47 | $51K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (2)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.
- F2. The shares of common stock underlying this stock option award vested as to 25% of the shares on April 6, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Shares sold: 599 shares
Sale price: $85.47/share
Options exercised: 599 shares
+3 more
6 metrics
Shares sold
599 shares
Common Stock sold on May 8, 2026
Sale price
$85.47/share
Open-market sale price for 599 common shares
Options exercised
599 shares
Common shares acquired via option exercise
Option exercise price
$8.44/share
Conversion or exercise price of stock option
Rule 10b5-1 plan adoption date
December 23, 2025
Plan governing the May 8, 2026 transaction
Option expiration
June 6, 2032
Expiration date of stock option (right to buy)
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), derivative security, open-market sale
4 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"Security title is listed as Stock Option (Right to Buy) for the derivative transaction."
derivative security financial
"The transaction code description notes an Exercise or conversion of derivative security."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"Transaction action is described as open-market sale for the common stock disposition."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Paula Soteropoulos report in this Form 4 for DNTH?
Paula Soteropoulos reported exercising stock options and selling shares of Dianthus Therapeutics common stock. She exercised options for 599 shares at $8.44 each, then sold 599 shares at $85.47 per share on May 8, 2026 under a Rule 10b5-1 plan.
What stock option exercise did the Dianthus Therapeutics director report?
She reported exercising a stock option covering 599 shares of common stock. The option had a conversion or exercise price of $8.44 per share and an expiration date of June 6, 2032, and the exercise was recorded as a derivative security transaction.
Was the Dianthus Therapeutics Form 4 transaction under a Rule 10b5-1 trading plan?
Yes. A footnote states the reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Such plans pre-schedule trades, indicating the timing of the May 2026 transactions was arranged in advance.
What vesting schedule applied to the Dianthus Therapeutics stock option in this Form 4?
The footnote explains the option’s underlying common shares vested 25% on April 6, 2023. The remaining three quarters then vested in equal monthly installments over the following three years, contingent on the reporting person’s continued service to the company on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
